| paclitaxel / Generic mfg. |
ChiCTR2100050475: Real world study to evaluate paclitaxel liposome / carboplatin combined with PD-1 monoclonal antibody in the first-line treatment of advanced lung squamous cell carcinoma |
|
|
| Recruiting | 4 | 88 | | Liposome paclitaxel + carboplatin + PD-1 | Cancer Hospital of Chinese Academy of Medical Sciences; Cancer Hospital of Chinese Academy of Medical Sciences, Nanjing LVYE Pharmaceutical Co., Ltd. | Squamous cell carcinoma of lung | | | | |
REaCT-OGF, NCT05753618: Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy |
|
|
| Recruiting | 4 | 240 | Canada | Granulocyte Colony-Stimulating Factor (G-CSF), Filgrastim, Pegfilgrastim, Omission of Granulocyte Colony-Stimulating Factor (G-CSF) | Ottawa Hospital Research Institute | Early-stage Breast Cancer | 10/25 | 10/25 | | |
ChiCTR2200066771: Efficacy and adverse reactions of radiotherapy combined with immunotherapy and chemotherapy in advanced non-small cell lung cancer: a prospective, non-randomized, concurrent, controlled clinical study |
|
|
| Not yet recruiting | 4 | 165 | China | Radiotherapy+Tislelizumab+Paclitaxel liposome+Cisplatin ;radiotherapy+Tislelizumab+Pemetrexed+Cisplatin ;Tislelizumab+Paclitaxel liposome+Cisplatin ;Tislelizumab+Pemetrexed+Cisplatin | Yiyang Center Hospital ; Yiyang Center Hospital, Chen Xiaoping Foundation、Scientific research Project of Hunan Provincial Health Commission、Hospital self-raised | Non-small Cell Lung Cancer | | | | |
ChiCTR2300075255: A single center, single arm clinical study on the treatment of advanced non-small cell lung cancer with positive EGFR sensitive mutations and failed EGFR TKIs with the combination of enrotinib and paclitaxel monoclonal antibody |
|
|
| Not yet recruiting | 4 | 52 | | Anlotinib combined with antipyridamab | The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital); The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital), Wu Jieping Medical Foundation | non-squamous non-small-cell lung cancer | | | | |
ChiCTR1900025137: A prospective, open, randomized, controlled clinical study for paclitaxel combined with cisplatin in the treatment of locally advanced esophageal squamous cell carcinoma |
|
|
| Not yet recruiting | 4 | 560 | | Taxol 135-175 mg/m2/d d1+ cisplatin 75mg/m2/d d1 q21d*2cycles ;Taxol 135-175 mg/m2/d d1+ cisplatin 75mg/m2/d d1 q21d*4cycles | Nanyang Central Hospital; Nanyang Central Hospital, self-raised | Esophageal squamous cell carcinomas | | | | |
DEXASTOP, NCT06118710: Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment |
|
|
| Not yet recruiting | 4 | 500 | Europe | Dexamethasone, H1 Antihistaminics | Erasmus Medical Center | Cancer | 01/27 | 08/27 | | |
ChiCTR2300074620: Adebrelimab combined with neoadjuvant chemotherapy for locally advanced cervical cancer: a single-arm, exploratory phase II clinical trial. |
|
|
| Not yet recruiting | 4 | 26 | | Adebrelimab + paclitaxel + cisplatin/carboplatin | The Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University, Hengrui Medicine | Cervical cancer | | | | |
ACTRN12606000316505: A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib (BAY 43-9006) in chemonaive patients with Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Bay 43-9006 / 11961 |
|
|
| Terminated | 3/4 | 926 | | | Bayer Australia Limited, Bayer Australia Ltd | Non-Small Cell Lung Cancer | | | | |
2007-004429-45: A randomised trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma |
|
|
| Ongoing | 3/4 | 375 | Europe | Carboplatin, Paclitaxel, Carboplatin, Paclitaxel, Carboplatin, Paclitaxel | Medical Research Council | Women with newly diagnosed, suspected, advanced (compatible with FIGO stage III/IV) ovarian, primary peritoneal or fallopian tube cancer who fulfil other entry criteria, with clinical and/or imaging evidence of extrapelvic metastatic disease at presentation and serum CA 125/CEA ratio > 25 | | | | |
2017-003221-15: PROSPEKTIV RANDOMISIERTE, MULTIZENTRISCHE STUDIE ZUMVERGLEICH DER EINER RADIKALEN HYSTEREKTOMIE NACHNEOADJUVANTER CHEMOTHERAPIE VERSUS EINER PRIMÄRENRADIOCHEMOTHERAPIE BEI PATIENTINNEN MIT EINEMZERVIXKARZINOMDER FIGO- STADIEN IB2 UND IIB |
|
|
| Not yet recruiting | 3/4 | 534 | Europe | CARBOPLATIN, Paclitaxel, Cisplatin, Ifosfamid | Universität zu Köln, Deutsche Krebshilfe | Patientinnen mit einem histologisch gesicherten Plattenepithel-,Adeno- oder adenosquamösen Zervixkarzinom FIGO StadiumIB2 oder IIB, Patientinnen mit einem histologisch gesicherten Plattenepithel-,Adeno- oder adenosquamösen Zervixkarzinom FIGO StadiumIB2 oder IIB, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
